Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.59 |
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.53 |
| ▸ | KLK7 | P49862 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 3/20 | 0.50 |
| ▸ | CTSS | P25774 | 4/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3108565 | 1.00 | SYK (0.59) | SYKKLK5KLK7ATMPPARA | |
| SCHEMBL1262680 | 1.00 | SYK (0.59) | SYKKLK5KLK7ATMPPARA | |
| SCHEMBL18976490 | 0.90 | SYK (0.57) | SYKKLK5KLK7ATMPPARA | |
| SCHEMBL31154007 | 0.90 | SYK (0.57) | SYKKLK5KLK7ATMPPARA | |
| SCHEMBL15928906 | 0.90 | ATM (0.62) | SYKKLK5KLK7ATMPPARA | |
| SCHEMBL17207697 | 0.90 | SYK (0.59) | SYKKLK5KLK7ATMPPARA | |
| SCHEMBL14119009 | 0.90 | ATM (0.62) | SYKKLK5KLK7ATMPPARA | |
| SCHEMBL6685926 | 0.90 | SYK (0.59) | SYKKLK5KLK7ATMPPARA | |
| SCHEMBL6685929 | 0.90 | SYK (0.59) | SYKKLK5KLK7ATMPPARA | |
| SCHEMBL5197783 | 0.90 | SYK (0.62) | SYKKLK5KLK7ATMPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340574-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | MAZE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12378206-B2 | Heteroaryl butanoic acid derivatives | NOVARTIS AG (CH) | 2025-08-05 | — | — | US | disclosed |
| US-20250197387-A1 | BCL-XL DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-06-19 | — | — | US | disclosed |
| WO-2025064952-A1 | BCL-2 INHIBITORS | Eil Therapeutics, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-12240862-B2 | Inhibitors of peptidylarginine deiminases | GILEAD SCIENCES, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| EP-4504739-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2025-02-12 | — | — | EP | disclosed |
| EP-4401729-A1 | BCL-XL DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| US-20240150377-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2024-05-09 | — | — | US | disclosed |
| US-11976083-B2 | Inhibitors of peptidylarginine deiminases | GILEAD SCIENCES, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-20170015637-A1 | NOVEL HETEROARYL BUTANOIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2017-01-19 | — | — | US | disclosed |
| US-20170015637-A1 | NOVEL HETEROARYL BUTANOIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2017-01-19 | — | — | US | disclosed |
| WO-2015092740-A1 | HETEROARYL BUTANOIC ACID DERIVATIVES AS LTA4H INHIBITORS | NOVARTIS AG (CH) | 2015-06-25 | — | — | WO | disclosed |
| EP-1330436-B1 | N-(4-ARYLOXYPIPERIDIN-1-YLALKYL) CINNAMIC AMIDES AS CCR3-3 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2010-06-30 | — | — | EP | disclosed |
| US-20070129371-A1 | Novel ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-20070129371-A1 | Novel ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| US-7034042-B2 | N-(4-aryloxypiperidin-1-ylalkyl) cinnamic amides as CCR33 receptor antagonists | NOVARTIS AG (CH) | 2006-04-25 | — | — | US | disclosed |
| US-20040087621-A1 | N-(4-aryloxypiperidin-1-ylalkyl) cinnamic amides as ccr33 receptor antagonists | NOVARTIS AG (CH) | 2004-05-06 | — | — | US | disclosed |
| EP-1330436-A1 | N-(4-ARYLOXYPIPERIDIN-1-YLALKYL) CINNAMIC AMIDES AS CCR3-3 RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2003-07-30 | — | — | EP | disclosed |
| WO-2002030898-A1 | N-(4-ARYLOXYPIPERIDIN-1-YLALKYL) CINNAMIC AMIDES AS CCR33 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129371-A1 | Novel ethylenediamine derivatives | C1R, C9, C1S | SYK 2242/4885KLK5 4138/4885KLK7 4271/4885 |
| US-12378206-B2 | Heteroaryl butanoic acid derivatives | LTA4H, LTC4S, LTB4R | SYK 4427/4885KLK5 3013/4885KLK7 4015/4885 |
| US-20250340574-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | SYK 3905/4885KLK5 4100/4885KLK7 4265/4885 |
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | APOL1, APOB, LDLR | SYK 4397/4885KLK5 2496/4885KLK7 3322/4885 |
| US-11976083-B2 | Inhibitors of peptidylarginine deiminases | PADI4, PADI2, PADI1 | SYK 2600/4885KLK5 3823/4885KLK7 4491/4885 |
| US-20040087621-A1 | N-(4-aryloxypiperidin-1-ylalkyl) cinnamic amides as ccr33 receptor antagonists | CCR1, CCR3, CCR8 | SYK 4125/4885KLK5 3864/4885KLK7 4015/4885 |
| US-20250197387-A1 | BCL-XL DEGRADERS AND USES THEREOF | XIAP, BCL2L1, BCL2L10 | SYK 1806/4885KLK5 4429/4885KLK7 4196/4885 |
| US-20170015637-A1 | NOVEL HETEROARYL BUTANOIC ACID DERIVATIVES | LTA4H, LTC4S, LTB4R | SYK 4485/4885KLK5 3017/4885KLK7 4031/4885 |
| US-12240862-B2 | Inhibitors of peptidylarginine deiminases | PADI4, PADI2, PADI1 | SYK 2600/4885KLK5 3823/4885KLK7 4491/4885 |
| US-20240150377-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | SYK 4109/4885KLK5 4189/4885KLK7 4326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.